Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction
Key Points
Perceptive Advisors increased its Apogee Therapeutics position by 978,662 shares; the estimated trade value was $61.64 million (based on quarterly average prices).
Meanwhile, the quarter-end position value rose by $122.20 million, including changes from both trading and price movements.
The post-trade stake stood at 2,330,651 shares valued at $175.92 million.
- 10 stocks we like better than Apogee Therapeutics ›
On February 17, 2026, Perceptive Advisors disclosed a buy of 978,662 shares of Apogee Therapeutics (NASDAQ:APGE), with an estimated transaction value of $61.64 million based on quarterly average pricing.
What happened
According to a February 17, 2026, SEC filing, Perceptive Advisors increased its stake in Apogee Therapeutics (NASDAQ:APGE) by 978,662 shares. The estimated transaction value was $61.64 million, based on the average share price during the fourth quarter of 2025. The fund ended the quarter holding 2,330,651 shares, with the value of the position rising by $122.20 million, reflecting both new purchases and share price appreciation.
What else to know
- This buy takes Apogee Therapeutics to 3.14% of Perceptive Advisors' 13F AUM as of December 31, 2025.
- Top holdings after the filing:
- NASDAQ:PRAX: $588.30 million (10.8% of AUM)
- NASDAQ:CELC: $315.20 million (5.8% of AUM)
- NASDAQ:RYTM: $272.57 million (5.0% of AUM)
- NASDAQ:ASND: $230.60 million (4.2% of AUM)
- NASDAQ:ROIV: $173.28 million (3.2% of AUM)
- As of February 17, 2026, shares were priced at $69.64, up 99.4% over the past year, outperforming the S&P 500 by 78.67 percentage points,
Company overview
| Metric | Value |
|---|---|
| Price (as of market close 2/17/26) | $69.64 |
| Market Capitalization | $3.82 billion |
| Net Income (TTM) | ($253.67 million) |
| One-Year Price Change | 99.37% |
Company snapshot
- Apogee Therapeutics develops biologic therapeutics targeting atopic dermatitis, chronic obstructive pulmonary disease, and related immunology indications, with lead candidates APG777 and APG808 in clinical development.
- The company operates a biotechnology model focused on research, clinical development, and eventual commercialization of proprietary monoclonal antibody therapies; revenue is expected to derive from product sales upon regulatory approval.
- It targets healthcare providers and patients affected by inflammatory and immunological diseases, with a primary focus on dermatology and respiratory markets.
Apogee Therapeutics, Inc. is a biotechnology company specializing in the development of extended half-life monoclonal antibodies for the treatment of atopic dermatitis and chronic obstructive pulmonary disease. The company leverages a pipeline of differentiated biologic candidates designed to address significant unmet needs in immunology. Apogee's strategy focuses on advancing its clinical programs to commercialization, aiming to establish a competitive position in targeted therapeutic markets.
What this transaction means for investors
Capital flows sometimes reveal more than headlines, and when a specialist biotech investor meaningfully adds to a name that has already doubled in a year, it signals conviction not just in momentum but in platform durability.
Apogee Enterprises recently delivered third-quarter net sales of $348.6 million, up 2.1% year over year, with adjusted EBITDA of $46.1 million and a 13.2% adjusted EBITDA margin. Diluted EPS came in at $0.77, or $1.02 on an adjusted basis. Management now expects fiscal 2026 sales of about $1.39 billion and adjusted diluted EPS between $3.40 and $3.50.
This is not a top holding, at just over 3% of 13F assets, especially compared with larger positions in names like Praxis or Celcuity. But the position still suggests this is a calculated growth allocation even if not a portfolio anchor.
Long term investors should focus on pipeline differentiation in atopic dermatitis and COPD, the extended half-life antibody approach, and capital discipline. A stock that has run about 100% can still compound if clinical execution matches ambition. The bet here looks sized for upside, not desperation.
Should you buy stock in Apogee Therapeutics right now?
Before you buy stock in Apogee Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Apogee Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $424,262!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,163,635!*
Now, it’s worth noting Stock Advisor’s total average return is 904% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 22, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool recommends Roivant Sciences. The Motley Fool has a disclosure policy.
Recommended Articles
